Trial Profile
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 01 Mar 2024 Results of Body composition measurements and clinical outcomes , published in the Journal of Gastrointestinal Surgery
- 06 Jun 2023 Results of a secondary analysis assessing prognostic role for chemotherapy dose density in patients undergoing perioperative presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 18 Oct 2022 Status changed from active, no longer recruiting to completed.